Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Roman Yatsyshyn
A Phase III Randomized Study to Evaluate the Efficacy and Safety of CT-P13 Compared With Reference Infliximab in Patients With Active Rheumatoid Arthritis: 54-Week Results From the PLANETRA Study
Arthritis Research & Therapy
Related publications
Efficacy and Safety of Tofacitinib as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis: A 12-Week, Randomized, Phase 2 Study
Modern Rheumatology
Medicine
Rheumatology
OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis
Switch From Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients With Moderate-To-Severe Rheumatoid Arthritis: 48-Week Results From the Phase III, Randomized, Double-Blind EQUIRA Study
Arthritis Research & Therapy
THU0218 the Efficacy and Drug Survival of the Biosimilar Infliximab (CT-P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results From the Turkbio Registry
Comparative Clinical Efficacy and Safety of the Proposed Biosimilar ABP 710 With Infliximab Reference Product in Patients With Rheumatoid Arthritis
Arthritis Research & Therapy
Phase III, Randomised, Double-Blind, Multicentre Study to Evaluate the Efficacy and Safety of Vonoprazan Compared With Lansoprazole in Asian Patients With Erosive Oesophagitis
Gut
Gastroenterology
Comparative Evaluation of the Long-Term Efficacy and Safety of the Infliximab Biosimilar BCD-055 and Reference Infliximab in Patients With Ankylosing Spondylitis: Results of the International Multicenter Randomized Double-Blind Phase Iii Clinical Study Asart-2
Nauchno-Prakticheskaya Revmatologiya
Rheumatology
Allergy
Immunology
Longterm (52-Week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients With Psoriatic Arthritis
Journal of Rheumatology
Rheumatology
Allergy
Immunology
Fri0087 Efficacy, Safety, and Immunogenicity Results of the Switch From Reference Adalimumab (Refadl) to Sandoz Biosimilar Adalimumab (Gp2017, SDZ-Adl) From Admyra Phase 3 Study in Patients With Moderate-To-Severe Rheumatoid Arthritis (Ra)
